EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Prostatic artery embolization and imaging-based biomarkers: current tools in monitoring treatment response and emerging strategies

Gavin Wu, Umairullah Lodhi, Robert Tenney, Mina S Makary, Jason C Hoffmann

Abdominal Radiology · 26.06.2026 · 51 (12) · 6358-6368

DOI: 10.1007/s00261-026-05628-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Abdominal Radiology, online erschienen am 26.06.2026. Verfasst von Gavin Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Ohio State University Wexner Medical Center, Columbus, USA. Gavin.Wu@osumc.edu. Hauptthemen laut MEDLINE: Embolization, Therapeutic, Prostatic Hyperplasia, Prostate, Lower Urinary Tract Symptoms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostatic artery embolization (PAE) is a safe and effective minimally invasive treatment for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), including in patients with large prostates, who are poor surgical candidates or wish to avoid the morbidity of conventional surgery or transurethral interventions. As PAE becomes more widely adopted for BPH-related LUTS, objective measures of assessing treatment response are needed beyond symptom-based tools such as the International Prostate Symptom Score (IPSS) and Quality-of-Life (QoL) index. Imaging biomarkers complement these subjective endpoints by quantifying structural, functional, ischemic, and microstructural changes within the prostate before and after embolization. This review summarizes the principal imaging modalities used for biomarker assessment in PAE, with emphasis on ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) scans, and examines the current literature on imaging biomarkers of treatment response. Volumetric biomarkers, including whole prostate volume, central gland volume, and zonal volumetry index, provide quantitative assessment of gland reduction and may help predict clinical improvement, with zonal parameters showing stronger associations with symptomatic outcomes than whole-gland measurements alone. Functional biomarkers such as postvoid residual volume offer objective evaluation of bladder emptying alongside volumetric assessment, whereas ischemia-based biomarkers derived from contrast-enhanced MRI directly reflect embolization-induced devascularization. Diffusion-weighted imaging and apparent diffusion coefficient mapping provide additional information regarding post-embolization tissue remodeling, with b-value selection influencing early infarct detection. Emerging tools, including ultrasound elastography, radiomics, and artificial intelligence-assisted image analysis, may further refine patient selection, standardize response assessment, and improve predictive modeling, though prospective PAE-specific validation remains needed. Imaging biomarkers provide a more objective framework for evaluating PAE treatment response, with the potential to standardize outcome reporting, facilitate earlier identification of treatment success or failure, and guide biomarker-driven clinical decision-making. Prospective validation in larger PAE-specific cohorts remains essential before broader clinical adoption.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Embolization, TherapeuticProstatic HyperplasiaProstateLower Urinary Tract SymptomsHumansMaleBiomarkersTreatment OutcomeMagnetic Resonance ImagingTomography, X-Ray ComputedArteries

Stichwörter der Autor:innen

Benign prostatic hyperplasiaImaging biomarkersLower urinary tract symptomsMagnetic resonance imagingProstate artery embolizationTreatment response

Substanzen

Biomarkers

Autor:innen und Institutionen

  • The Ohio State University Wexner Medical Center, Columbus, USA. Gavin.Wu@osumc.edu.
  • NYU Langone Hospital - Long Island, Mineola, USA.
  • The Ohio State University Wexner Medical Center, Columbus, USA.

Zitieren

APA

Wu, G., Lodhi, U., Tenney, R., Makary, M. S., & Hoffmann, J. C. (2026). Prostatic artery embolization and imaging-based biomarkers: current tools in monitoring treatment response and emerging strategies. Abdominal Radiology, 51(12), 6358-6368. https://doi.org/10.1007/s00261-026-05628-5

Vancouver

Wu G, Lodhi U, Tenney R, Makary MS, Hoffmann JC. Prostatic artery embolization and imaging-based biomarkers: current tools in monitoring treatment response and emerging strategies. Abdominal Radiology. 2026;51(12):6358-6368. doi:10.1007/s00261-026-05628-5

BibTeX
@article{Wu2026,
  author = {Wu, Gavin and Lodhi, Umairullah and Tenney, Robert and Makary, Mina S and Hoffmann, Jason C},
  title = {Prostatic artery embolization and imaging-based biomarkers: current tools in monitoring treatment response and emerging strategies},
  journal = {Abdominal Radiology},
  year = {2026},
  volume = {51},
  number = {12},
  pages = {6358--6368},
  doi = {10.1007/s00261-026-05628-5}
}
Kostenlos starten →